Mingzhao Wang

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers.

Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers.

Journal: International journal of cancer

Published: February 25, 2025

Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

Journal: International immunopharmacology

Published: November 23, 2024

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.

Journal: Cell & bioscience

Published: May 06, 2024

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.

Journal: Cancer cell international

Published: November 27, 2023

Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.

Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.

Journal: Thoracic cancer

Published: December 13, 2022

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.

Journal: Cancer medicine

Published: December 13, 2022

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.

Journal: Frontiers in immunology

Published: November 01, 2022

PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.

PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.

Journal: Journal of cancer research and clinical oncology

Published: April 04, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026